Literature DB >> 30737318

Signaling dynamics of DNA damage response invoked by combination therapy are dose-dependent.

Siang-Boon Koh1.   

Abstract

Mesh：

Year:  2019        PMID： 30737318      PMCID： PMC6369282          DOI： 10.1074/jbc.L119.007381

Source DB:  PubMed          Journal:  J Biol Chem        ISSN： 0021-9258            Impact factor:   5.157


× No keyword cloud information.
  5 in total

1.  Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine.

Authors:  Siang-Boon Koh; Yann Wallez; Charles R Dunlop; Sandra Bernaldo de Quirós Fernández; Tashinga E Bapiro; Frances M Richards; Duncan I Jodrell
Journal:  Cancer Res       Date:  2018-05-07       Impact factor: 12.701

Review 2.  Cellular pharmacology of gemcitabine.

Authors:  E Mini; S Nobili; B Caciagli; I Landini; T Mazzei
Journal:  Ann Oncol       Date:  2006-05       Impact factor: 32.976

3.  Inhibition of checkpoint kinase 1 following gemcitabine-mediated S phase arrest results in CDC7- and CDK2-dependent replication catastrophe.

Authors:  Nicholas J H Warren; Alan Eastman
Journal:  J Biol Chem       Date:  2018-12-20       Impact factor: 5.157

4.  CHK1 Inhibition Synergizes with Gemcitabine Initially by Destabilizing the DNA Replication Apparatus.

Authors:  Siang-Boon Koh; Aurélie Courtin; Richard J Boyce; Robert G Boyle; Frances M Richards; Duncan I Jodrell
Journal:  Cancer Res       Date:  2015-07-03       Impact factor: 12.701

Review 5.  Gemcitabine: metabolism, mechanisms of action, and self-potentiation.

Authors:  W Plunkett; P Huang; Y Z Xu; V Heinemann; R Grunewald; V Gandhi
Journal:  Semin Oncol       Date:  1995-08       Impact factor: 4.929
  5 in total
  1 in total

1.  Reply to Koh: Signaling dynamics of DNA damage response invoked by combination therapy are dose-dependent.

Authors:  Nicholas J H Warren; Alan Eastman
Journal:  J Biol Chem       Date:  2019-02-08       Impact factor: 5.157
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.